Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.

Share:
Related BMY
These Were The Most Popular Buys And Sells Among Retail Investors In June
TD Ameritrade's Investor Movement Index (IMX) For June 2017
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Bristol Myers Squibb Co. (NYSE: BMY), and slightly raised its price target from $38.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Bristol Myers Squibb Co. closed on Tuesday at $34.22.

Latest Ratings for BMY

DateFirmActionFromTo
Jul 2017Deutsche BankMaintainsHold
May 2017BMO CapitalDowngradesMarket PerformUnderperform
Dec 2016JefferiesUpgradesHoldBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!